News Story Headlines
May 3, 2023
Ultromics granted FDA Breakthrough Device Designation for AI-enhanced Cardiac Amyloidosis detection
26th April 2023 | By Ultromics
Oxford, UK, April 26th, 2023 — Ultromics, a leader in the field of artificial intelligence-powered diagnostics for heart failure, has been granted FDA Breakthrough Device Status...
April 24, 2023
NEURO-TTRansform Phase III results presented at AAN showed eplontersen demonstrated consistent and sustained improvement in all measures of disease and quality of life through 66 weeks
April 24, 2023 07:00 AM Eastern Daylight Time
WILMINGTON, Del.–(BUSINESS WIRE)–Detailed results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy...
April 24, 2023
2023 Spring Newsletter
Be sure to catch up on the latest happenings in our spring newsletter here!
March 27, 2023
Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyretin-mediated amyloid polyneurophathy (ATTRv-PN) through 66 weeks
Published 27 March 2023
Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed eplontersen met its co-primary endpoints through 66 weeks....
February 2, 2023
2023 Winter Newsletter
Be sure to catch up on the latest happenings in our winter newsletter here!